PMC8685498_01
PMC8685498_02
PMC8685498_03
Summary of the treatment carried out by the patient over time (doses of the drugs are intended as daily and of omalizumab as every 2 weeks).
fped-09-675281-g0001.jpg
PMC8685498_03_fped-09-675281-g0001.jpg
F1
Allergy Unit, where spirometry was performed each time as well. Afterwards, at 16 years old, her asthma clinical manifestations worsened progressively, becoming severe despite treatment with high-dose inhaled corticosteroid, long-acting beta2-agonist, and anti-leukotriene (fluticasone/salmeterol and montelukast) (Figure 1). The patient's clinical condition benefitted from the treatment with omalizumab (Figures 1, 2), with clinical improvements after the first injection and with an improvement of the spirometry (FEV1 = 94%, with a negative bronchodilatation test) performed after the seventh injection. At that time, the patient had been undergoing therapy with subcutaneous omalizumab every 2 weeks for about 3 months, as well as fluticasone/salmeterol and montelukast daily (Figure 1).
Summary of the Asthma Control Test recorded with the patient over time.
fped-09-675281-g0002.jpg
PMC8685498_03_fped-09-675281-g0002.jpg
F2
The patient's clinical condition benefitted from the treatment with omalizumab (Figures 1, 2), with clinical improvements after the first injection and with an improvement of the spirometry (FEV1 = 94%, with a negative bronchodilatation test) performed after the seventh injection. It is worth mentioning that the patient remained free of asthma clinical manifestations the whole time she was positive of SARS-CoV-2, without significant differences in asthma management during this period (Figure 2).